Tryptophan Hydroxylase 1 anticorps (full length)

N° du produit ABIN7879211

Cet anticorps Souris Monoclonal détecte spécifiquement Tryptophan Hydroxylase 1 dans IHC (p). Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Tryptophan Hydroxylase 1 anticorps (full length) (ABIN7879211)

Antigène: Tryptophan Hydroxylase 1 (TPH1)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Tryptophan Hydroxylase 1 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: TPH1-7662

Détail du produit anti-Tryptophan Hydroxylase 1 anticorps

Épitope: full length

Fonction: Tryptophan Hydroxylase 1 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: Recombinant full-length human TPH1 protein was used as the immunogen for the Tryptophan Hydroxylase 1 antibody.

Isotype: IgG2, kappa

Information d'application

Indications d'application: Optimal dilution of the Tryptophan Hydroxylase 1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the Tryptophan Hydroxylase 1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur Tryptophan Hydroxylase 1

Antigène: Tryptophan Hydroxylase 1 (TPH1)

Autre désignation: Tryptophan Hydroxylase 1

Sujet: Phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) comprise a small family of monooxygenases that use tetrahydropterine as a cofactor during the catabolism of aromatic L-amino acids. PAH, TH and TPH all contain catalytic domains with an amino-terminal regulatory domain and a short carboxy-terminal tetramerization domain. Each of these enzymes also contains a single ferrous iron atom, which is bound to two histidines and a glutamate, and is likely to be involved in the formation of the hydroxylating intermediate. TPH is both the first and rate-limiting-step in the biosynthesis of serotonin in the central nervous system and melatonin in the pineal gland. Alteration of TPH function may be a key factor in the pathology of several neuropsychiatric disorders associated with serotonin, including depression, aggression, alcoholism and schizophrenia. For instance, LDOPA, which is used as a common therapy for Parkinson s disease (PD) patients, inhibits TPH function which, subsequently, is thought to contribute to the onset of depression in PD patients.

UniProt: P17752

Pathways: Feeding Behaviour